| 中文名稱 | P27抗體/周期素依賴激酶抑制劑 |
| 別 名 | p27 KIP 1; CDN1B_HUMAN; AA408329; AI843786; Cdki1b; CDKN 1B; CDKN 4; CDKN1B; CDKN1B; CDKN4; CDKN4; Cyclin Dependent Kinase Inhibitor 1B; Cyclin Dependent Kinase Inhibitor 1B; Cyclin dependent kinase inhibitor p27; Cyclin dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B (p27, Kip1); Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27 Kip1; KIP 1; KIP1; MEN1B; MEN4; OTTHUMP00000195098; OTTHUMP00000195099; p27; p27 Kip1; P27-like cyclin-dependent kinase inhibitor; P27KIP1. |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 染色質(zhì)和核信號 信號轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Chicken, Dog, Pig, Sheep, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/Test ICC=1:100 IF=1:200-800 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 22kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human P27 kip1:101-198/198 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | Cell cycle progression is regulated by cyclins and their cognate Cdks. p27 KIP 1 is a cell cycle regulatory mitotic inhibitor of cdk activity. p27 KIP 1 is a candidate tumor suppressor gene, and has been proposed to function as a possible mediator of TGF beta induced G1 arrest. p27 KIP 1 is up regulated in response to antimitogenic stimuli. The increased protein expression of p27 results in cellular arrest by binding to cyclin/Cdk complexes such as cyclin D1/Cdk4. p27 Kip1 is regulated by phosphorylation on serine 10 (S10) and threonine 187 (T187). Phosphorylation by CDK2 on T187 results in ubiquitylation and degradation of p27 Kip 1; while phosphorylation by hKIS on S10 signals the nuclear export to the cytoplasm. Function: Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. Subunit: Forms a ternary compex with CCNE1/CDK2/CDKN1B. Subcellular Location: Nucleus. Cytoplasm. Endosome. Note=Nuclear and cytoplasmic in quiescent cells. AKT-or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6; this leads to lysosomal degradation. Tissue Specificity: Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney. Post-translational modifications: Phosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF. Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation. DISEASE: Defects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2. Similarity: Belongs to the CDI family. SWISS: P46527 Gene ID: 1027 Database links: Entrez Gene: 1027 Human Entrez Gene: 12576 Mouse Entrez Gene: 83571 Rat Omim: 600778 Human SwissProt: P46527 Human SwissProt: P46414 Mouse Unigene: 238990 Human Unigene: 2958 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. P27蛋白是一種新發(fā)現(xiàn)的周期素依賴激酶抑制劑，屬于細(xì)胞周期的負(fù)性調(diào)控因子。P27基因及其產(chǎn)物的異常表達(dá)可能與某些腫瘤的發(fā)生、發(fā)展有著密切的關(guān)系。P27蛋白對細(xì)胞周期的調(diào)控及在腫瘤中發(fā)揮著很重要的作用，細(xì)胞核表達(dá)。 |
| 產(chǎn)品圖片 |  Sample: Hela Cell (Human) Lysate at 40 ugPrimary: Anti-CDKN1B/p27 KIP 1 (bs-0742R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 22 kD Observed band size: 24 kD  CDKN1B (p27Kip1) was immunoprecipitated from mouse kidney tissue with bs-0742R at 1/150 dilution. Western blot was performed from the immunoprecipitate using protein A/G beads. HRP Conjugated Goat anti-Rabbit IgG (Heavy Chain specific) was used as secondary antibody at 1:5000 dilution.Lane 1: mouse kidney tissue lysate 10 µg (Input). Lane 2: bs-0742R IP in mouse kidney tissue lysate. Lane 3: native rabbit IgG IP in mouse kidney tissue lysate (negative control). Secondary All lanes Goat anti-Rabbit IgG (Heavy Chain specific), HRP Conjugated, 1:5000  Sample:293T(Human) Cell Lysate at 30 ug Primary: Anti- CDKN1B'p27 KIP 1 (bs-0742R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 22 kD Observed band size: 22 kD  Sample:293T(Human) Cell Lysate at 30 ug U2os(Human) Cell Lysate at 30 ug Primary: Anti- CDKN1B’p27 KIP 1 (bs-0742R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 22 kD Observed band size: 22 kD  Sample:Brain (Mouse) Lysate at 40 ug Primary: Anti- CDKN1B'p27 KIP 1 (bs-0742R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 22 kD Observed band size: 22 kD Tissue/cell: human ovary carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37∩ for 20 min; Incubation: Anti-CDKN1B/P27kip1 Polyclonal Antibody, Unconjugated(bs-0742R) 1:200, overnight at 4∑C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining  Tissue/cell: MCF7; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (CDKN1B ) Polyclonal Antibody, Unconjugated (bs-0742R) 1:200, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody (bs-0295G-FITC) at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei. Blank control: RSC96(blue), the cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice.Isotype Control Antibody: Rabbit IgG(orange) ; Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA ; Primary Antibody Dilution: 1μg in 100μL1X PBS containing 0.5% BSA(green). |
我要詢價
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會被公開)
*內(nèi)容：
